Splicing factor PRPF31 retinitis pigmentosa (RP11) is caused by disrupted alternative splicing programmes for genes implicated in pre-mRNA splicing, cellular adhesion and ciliogenesis.
Adriana Buskin(Newcastle University), Majlinda Lako(Newcastle University), Yuchun Ding(Chongqing Academy of Animal Science), Gerrit Hilgen(Northumbria University), Sina Mozaffari‐Jovin(Mashhad University of Medical Sciences), Kuan‐Ting Pan(Max Planck Institute for Biophysical Chemistry), Martin McKibbin(Leeds Teaching Hospitals NHS Trust), Valeria Chichagova(Newcastle University), Susan Lindsay(Centre for Life), Revital Bronstein(Massachusetts Eye and Ear Infirmary), Colin A. Johnson(University of Leeds), S. Zwolinski, David Steel(Sunderland Eye Infirmary), Natalio Krasnogor(Newcastle University), Sudeep Mehrotra, Basudha Basu(University of Leeds), David J. Elliott(Newcastle University), Sameer Alharthi(Queen Mary University of London), Kathryn White(Newcastle University), Eric A. Pierce(Massachusetts Eye and Ear Infirmary), Evelyne Sernagor(Newcastle University), Chris F. Inglehearn(University of Leeds), Stefan Przyborski(Durham University), Dean Hallam(Newcastle University), Jumana Y. Al‐Aama(King Abdulaziz University), Lyle Armstrong(Newcastle University), Gabrielle Wheway(University of Southampton), Yaobo Xu(Newcastle University), Michael H. Farkas(Buffalo State University), Robin R. Ali(Cell and Gene Therapy Catapult), Katarzyna Szymańska(University of Michigan), Alastair Droop(Wellcome Sanger Institute), Katarzyna Bialas(Newcastle University), Sushma‐Nagaraja Grellscheid(Durham University), Henning Urlaub(Bioanalytica (Switzerland)), Achim Treumann(Newcastle University), Carla Mellough(Newcastle University), David Dolan(University of Bergen)
Durham Research Online (Durham University)
January 1, 2019
Cited by 0
Related Papers
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
|Proceedings of the National Academy of Sciences|1995|1.3k
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|857
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration
|Molecular Therapy|2009|551